Vapendavir

Drug Profile

Vapendavir

Alternative Names: BTA-798

Latest Information Update: 31 Aug 2016

Price : $50

At a glance

  • Originator Biota Holdings
  • Developer Aviragen Therapeutics; Biota Pharmaceuticals
  • Class Antivirals; Benzoxazoles; Small molecules
  • Mechanism of Action Rhinovirus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rhinovirus infections

Most Recent Events

  • 01 Aug 2016 Aviragen Therapeutics completes a phase I bioavailability trial in Healthy volunteers in USA (PO, Tablet and Suspension) (NCT02877264)
  • 01 Jun 2016 Phase-I clinical trials in Rhinovirus infections (In volunteers) in USA (PO, Suspension) (NCT02877264)
  • 01 Jun 2016 Aviragen Therapeutics initiates a phase I bioavailability trial in Healthy volunteers in USA (PO, Tablet) (NCT02877264)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top